» Articles » PMID: 22836651

Neurological Paraneoplastic Syndromes in Lung Cancer Patients

Overview
Date 2012 Jul 28
PMID 22836651
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is recognized among the most frequent causes of paraneoplastic neurological syndromes (PNS). Neurological syndromes in subjects with systemic malignancy remain a clinical and diagnostic challenge. The aim of the study was to evaluate the frequency of NPS, their clinical manifestation and association with onconeural antibodies in patients with lung cancer. Fifty patients hospitalized with the diagnosis of PNS participated in the study. Neurological evaluation consisted of the Rankin scale (mRS), the Barthel index (BI), and testing for the presence of onconeural antibodies by means of indirect immunofluorescence, as screening, and Western blotting as confirmation. The majority of lung cancer patients (64%) aged 62 ± 10 had NPS symptoms. Their neurological condition and daily living activities were reasonable: mRS (1.0; 0.0-4.0) and BI (100; 7.4-100) scores. Classical PNS were found in 30% of cases and included sensory neuropathy (16%), paraneoplastic cerebellar degeneration (12%) as the most frequent symptoms. Autoimmune reaction was observed in 42% of lung cancer patients and in 20% was represented by well-characterized onconeural antibodies. Anti-Hu antibody was identified as the most frequent. In conclusion, PNS signs in lung cancer patients have both classical and non-classical features. In the course of SCLC only well-characterized onconeural antibodies were identified. The presence of well-characterized onconeural antibodies is strongly associated with classical features of PNS.

Citing Articles

TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients.

Tomanovic Vujadinovic S, Ilic N, Selakovic I, Nedeljkovic U, Krstic N, Mujovic N Medicina (Kaunas). 2022; 58(10).

PMID: 36295566 PMC: 9611034. DOI: 10.3390/medicina58101405.


Neurological paraneoplastic syndrome caused by small cell lung cancer: a case report.

Yan W, Wang X, Wang Y, Liu L Transl Cancer Res. 2022; 9(4):2999-3002.

PMID: 35117656 PMC: 8798883. DOI: 10.21037/tcr.2020.03.54.


Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy.

Zaborowski M, Stefens-Stawna P, Osztynowicz K, Piorunek T, Batura-Gabryel H, Dyzmann-Sroka A Cancer Immunol Immunother. 2020; 70(5):1277-1289.

PMID: 33136178 PMC: 8053162. DOI: 10.1007/s00262-020-02750-1.


Various clinical features of patients with anti-Hu associated paraneoplastic neurological syndromes: An observational study.

Li J, Lin W Medicine (Baltimore). 2018; 97(18):e0649.

PMID: 29718880 PMC: 6392975. DOI: 10.1097/MD.0000000000010649.


Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.

Abboud H, Rossman I, Mealy M, Hill E, Thompson N, Banerjee A J Neurol. 2017; 264(11):2284-2292.

PMID: 28975404 DOI: 10.1007/s00415-017-8627-4.